Michael Cartwright to Disease Progression
This is a "connection" page, showing publications Michael Cartwright has written about Disease Progression.
Connection Strength
0.224
-
Wosiski-Kuhn M, Robinson M, Strupe J, Arounleut P, Martin M, Caress J, Cartwright M, Bowser R, Cudkowicz M, Langefeld C, Hawkins GA, Milligan C. IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e631.
Score: 0.145
-
Shefner JM, Rutkove SB, Caress JB, Benatar M, David WS, Cartwright MS, Macklin EA, Bohorquez JL. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener. 2018 11; 19(7-8):555-561.
Score: 0.034
-
Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Benatar M, Sharma KR, Narayanaswami P, Raynor EM, Watson ML, Shefner JM. Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve. 2014 Mar; 49(3):441-3.
Score: 0.024
-
Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Clawson L, Benatar M, Usher S, Sharma KR, Gautam S, Narayanaswami P, Raynor EM, Watson ML, Shefner JM. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012 Sep; 13(5):439-45.
Score: 0.022